TScan promotes Gavin MacBeath to CSO and COO; salary raised to $470k

TScan Therapeutics, Inc.

Gavin MacBeath, Ph.D., promoted from CSO to Chief Scientific and Operations Officer effective June 1, 2022.
Annual base salary increased to $470,000 in connection with promotion.
Stockholders elected Timothy Barberich and Stephen Biggar as Class I directors for three-year terms.
Ratification of Deloitte & Touche as independent auditor for FY2022 approved with 11.5M votes for, 425 against.
All votes at Annual Meeting held June 1, 2022; results filed via 8-K.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Gavin MacBeath

Chief Scientific and Operations Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2022-06-01
Filed: June 3, 2022, 7:59 PM ET

On June 1, 2022, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) promoted Gavin MacBeath, Ph.D. to Chief Scientific and Operations Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gavin MacBeath changed role as Chief Scientific and Operations Officer at TScan Therapeutics, Inc..

Action: promoted
Role: Chief Scientific and Operations Officer

Exact text from the filing

On June 1, 2022, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) promoted Gavin MacBeath, Ph.D. to Chief Scientific and Operations Officer.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-167299

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.